Serum Institute gets approval to resume Indian trial of AstraZeneca COVID vaccine-source
AstraZeneca has resumed British clinical trials of the vaccine - one of the most advanced in development for COVID-19 - after they were paused earlier this month following a serious side effect in a trial participant. Trials have also resumed in Brazil and South Africa.
- Country:
- India
Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca's potential COVID-19 vaccine, a source familiar with the matter said on Wednesday.
The approval came from the Drugs Controller General of India, the source said. AstraZeneca has resumed British clinical trials of the vaccine - one of the most advanced in development for COVID-19 - after they were paused earlier this month following a serious side effect in a trial participant.
Trials have also resumed in Brazil and South Africa. The trial remains on hold in the United States, the U.S. Food and Drug Administration's top official confirmed on Tuesday.
Serum, the world's biggest vaccine manufacturer, did not immediately respond to Reuters' requests for comment. The DCGI did not return an email seeking comment.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
South African policymakers discussing lower inflation target – Kganyago
SANDF refutes claims that South African soldiers being held by M23
India at G20 Sherpa meeting expresses support for Brazilian presidency's priority of reducing inequalities
Study finds mercury contamination in Brazil's Yanomami people
South Africa's parliament speaker resigns over accusations of bribery